Short-term effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men

Cholesterol

Volumn 2013, Issue , 2013, Pages

  Kakuda, Hirokazu ^a   Kobayashi, Junji ^b   Nakato, Mio ^b   Takekoshi, Noboru ^b  

^a Kakuda Clinic   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893751761     PISSN: 20901283     EISSN: 20901291     Source Type: Journal    
DOI: 10.1155/2013/314170     Document Type: Article

References (40)

1. Qiao Q., Larsen S., Borch-Johnsen K., Nissinen A., Pekkanen J., Tuomilehto J., Jousilahti P., Lindstrøm J., Pyörälä M., Pyorala K., Balkau B., Eschwege E., Gallus G., Garancini M. P., Bouter L. M., Dekker J. M., Heine R. J., Nijpels G., Stehouwer C. D. A., Feskens E. J. M., Kromhout D., Peltonen M., Pajak A., Eriksson J., Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine 2001 161 3 397 405 2-s2.0-0035847591 (Pubitemid 32116556)
2. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A., Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999 22 6 920 924 2-s2.0-0033047374 10.2337/diacare.22.6.920 (Pubitemid 29241045)
3. Zilversmit D. B., Atherogenesis: a postprandial phenomenon. Circulation 1979 60 3 473 485 2-s2.0-0018649439 (Pubitemid 9254048)
4. Karpe F., Postprandial lipoprotein metabolism and atherosclerosis. Journal of Internal Medicine 1999 246 4 341 355 2-s2.0-0032852279 10.1046/j.1365-2796.1999.00548.x (Pubitemid 29479916)
5. Havel R. J., Remnant lipoproteins as therapeutic targets. Current Opinion in Lipidology 2000 11 6 615 620 2-s2.0-0033669114 10.1097/00041433-200012000- 00008
6. Aronson D., Rayfield E. J., How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovascular Diabetology 2002 1, article 1 2-s2.0-1642616527 10.1186/1475-2840-1-1 (Pubitemid 38751088)
7. Twickler T. B., Dallinga-Thie G. M., Cohn J. S., Chapman M. J., Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004 109 16 1918 1925 2-s2.0-2142708629 10.1161/01.CIR.0000125278.58527.F3 (Pubitemid 38544478)
8. Varbo A., Benn M., Tybjaerg-Hansen A., Jorgensen A. B., Frikke-Schmidt R., Nordestgaard B. G., Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American College of Cardiology 2013 61 427 436
9. Ooi T. C., Cousins M., Ooi D. S., Nakajima K., Edwards A. L., Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia. Atherosclerosis 2004 172 2 375 382 2-s2.0-0842324553 10.1016/j.atherosclerosis.2003.10.016 (Pubitemid 38167549)
10. Schaefer E. J., McNamara J. R., Tayler T., Daly J. A., Gleason J. L., Seman L. J., Ferrari A., Rubenstein J. J., Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. The American Journal of Cardiology 2004 93 1 31 39 2-s2.0-0346733215 10.1016/j.amjcard.2003.09.008 (Pubitemid 38022030)
11. Schneider J. G., Von Eynatten M., Parhofer K. G., Volkmer J. E., Schiekofer S., Hamann A., Nawroth P. P., Dugi K. A., Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 2004 175 2 325 331 2-s2.0-3242738678 10.1016/j.atherosclerosis. 2004.04.003 (Pubitemid 38942913)
12. Schoonjans K., Peinado-Onsurbe J., Fruchart J.-C., Tailleux A., Fiévet C., Auwerx J., 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Letters 1999 452 3 160 164 2-s2.0-0033006201 10.1016/S0014-5793(99)00632-8 (Pubitemid 29301736)
13. Parhofer K. G., Barrett P. H. R., Schwandt P., Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. The Journal of Clinical Endocrinology and Metabolism 2000 85 11 4224 4230 2-s2.0-0034527609 10.1210/jc.85.11.4224 (Pubitemid 32055377)
14. Parhofer K. G., Laubach E., Barrett P. H. R., Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. Journal of Lipid Research 2003 44 6 1192 1198 2-s2.0-0142042354 10.1194/jlr.M300011-JLR200 (Pubitemid 37279637)
15. Yunoki K., Nakamura K., Miyoshi T., Enko K., Kohno K., Morita H., Kusano K. F., Ito H., Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011 217 2 486 491 2-s2.0-79960698721 10.1016/j.atherosclerosis.2011.04.019
16. Hayashi T., Yokote K., Saito Y., Iguchi A., Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opinion on Pharmacotherapy 2007 8 14 2315 2327 2-s2.0-35548994573 10.1517/14656566.8.14.2315 (Pubitemid 350001592)
17. Hiro T., Kimura T., Morimoto T., Miyauchi K., Nakagawa Y., Yamagishi M., Ozaki Y., Kimura K., Saito S., Yamaguchi T., Daida H., Matsuzaki M., Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). Journal of the American College of Cardiology 2009 54 4 293 302 2-s2.0-67650095320 10.1016/j.jacc.2009.04.033
18. Kawashiri M.-A., Nohara A., Tada H., Mori M., Tsuchida M., Katsuda S., Inazu A., Kobayashi J., Koizumi J., Mabuchi H., Yamagishi M., Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clinical Pharmacology and Therapeutics 2008 83 5 731 739 2-s2.0-42349116146 10.1038/sj.clpt.6100396 (Pubitemid 351556020)
19. Poolsup N., Suksomboon N., Wongyaowarat K., Rungkanchananon B., Niyomrat P., Kongsuwan S., Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. Journal of Clinical Pharmacy and Therapeutics 2012 37 2 166 172 2-s2.0-84857994339 10.1111/j.1365-2710.2011.01274.x
20. Corsini A., Ceska R., Drugdrug interactions with statins: will pitavastatin overcome the statins Achilles heel? Current Medical Research and Opinion 2011 27 8 1551 1562 2-s2.0-79960400093 10.1185/03007995.2011.589433
21. Catapano A. L., Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular Reference to pitavastatin. Current Vascular Pharmacology 2012 10 2 257 267 2-s2.0-84857127538 10.2174/157016112799305021
22. Nagashima H., Endo M., Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart and Vessels 2011 26 4 428 434 2-s2.0-80051474919 10.1007/s00380-010-0071-7
23. Arao K., Yasu T., Umemoto T., Jinbo S., Ikeda N., Ueda S., Kawakami M., Momomura S.-I., Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circulation Journal 2009 73 8 1523 1530 2-s2.0-69049107753 10.1253/circj.CJ-08- 0917
24. Aoki T., Yoshinaka Y., Yamazaki H., Suzuki H., Tamaki T., Sato F., Kitahara M., Saito Y., Triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipemia. European Journal of Pharmacology 2002 444 1-2 107 113 2-s2.0-0037165840 10.1016/S0014-2999(02)01547-9 (Pubitemid 34621340)
25. Nuernberg A. M., Boyce P. D., Cavallari J. M., Fang S. C., Eisen E. A., Christiani D. C., Urinary 8-isoprostane and 8-OHdG concentrations in boilermakers with welding exposure. Journal of Occupational and Environmental Medicine 2008 50 2 182 189 2-s2.0-40049099865 10.1097/JOM.0b013e31815cf6cc (Pubitemid 351321686)
26. Commodore A. A., Zhang J. J., Chang Y., Concentrations of urinary 8-hydroxy-2'-deoxyguanosine and 8-isoprostane in women exposed to woodsmoke in a cookstove intervention study in San Marcos, Peru. Environment International 2013 60 112 122
27. Morrow J. D., Hill K. E., Burk R. F., Nammour T. M., Badr K. F., Roberts L. J. II, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America 1990 87 23 9383 9387 2-s2.0-0025572704 10.1073/pnas.87.23.9383 (Pubitemid 120030630)
28. Nagai E., Katsuno T., Miyagawa J.-I., Konishi K., Miuchi M., Ochi F., Kusunoki Y., Tokuda M., Murai K., Hamaguchi T., Namba M., Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocrine Journal 2011 58 10 869 877 2-s2.0-80055082813 10.1507/endocrj.K11E-129
29. McNamara J. R., Shah P. K., Nakajima K., Cupples L. A., Wilson P. W. F., Ordovas J. M., Schaefer E. J., Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001 154 1 229 236 2-s2.0-0035177104 10.1016/S0021-9150(00)00484-6 (Pubitemid 32010711)
30. Karpe F., Boquist S., Tang R., Bond G. M., De Faire U., Hamsten A., Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. Journal of Lipid Research 2001 42 1 17 21 2-s2.0-0035135827 (Pubitemid 32142856)
31. Guerin M., Egger P., Goff W. L., Soudant C., Dupuis R., John Chapman M., Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIB hyperlipidemia. The Journal of Clinical Endocrinology and Metabolism 2002 87 11 4991 5000 2-s2.0-0036846531 10.1210/jc.2002-020298 (Pubitemid 35316337)
32. Saiki A., Murano T., Watanabe F., Oyama T., Miyashita Y., Shirai K., Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. Journal of Atherosclerosis and Thrombosis 2005 12 3 163 168 2-s2.0-26944457749
33. Morikawa S., Umetani M., Nakagawa S., Yamazaki H., Suganami H., Inoue K., Kitahara M., Hamakubo T., Kodama T., Saito Y., Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. Journal of Atherosclerosis and Thrombosis 2000 7 3 138 144 2-s2.0-0034570787
34. Lally S., Tan C. Y., Owens D., Tomkin G. H., Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006 49 5 1008 1016 2-s2.0-33646412333 10.1007/s00125-006-0177-8
35. Bae J.-H., Bassenge E., Kim K.-B., Kim Y.-N., Kim K.-S., Lee H.-J., Moon K.-C., Lee M.-S., Park K.-Y., Schwemmer M., Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 2001 155 2 517 523 2-s2.0-0035096964 10.1016/S0021-9150(00)00601-8 (Pubitemid 32209324)
36. Carnevale R., Pignatelli P., Di Santo S., Bartimoccia S., Sanguigni V., Napoleone L., Tanzilli G., Basili S., Violi F., Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis 2010 213 1 225 234 2-s2.0-77958486858 10.1016/j.atherosclerosis.2010.08.056
37. Nomura S., Inami N., Shouzu A., Omoto S., Kimura Y., Takahashi N., Tanaka A., Urase F., Maeda Y., Ohtani H., Iwasaka T., The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 2009 20 1 16 22 2-s2.0-61649116419 10.1080/09537100802409921
38. Kakuda H., Kanasaki K., Koya D., Takekoshi N., The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects. Clinical and Experimental Nephrology 2013 17 240 247
39. Sadowitz B., Maier K. G., Gahtan V., Basic science review: statin therapy-part I: the pleiotropic effects of statins in cardiovascular disease. Vascular and Endovascular Surgery 2010 44 4 241 251 2-s2.0-77951716673 10.1177/1538574410362922
40. Bech J. N., Nielsen C. B., Pedersen E. B., Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. American Journal of Physiology 1996 270 5 F845 F851 2-s2.0-0029893249